market size 2012 | onderstepoort biological products © |22nd february 2013page 21 estimated market...

10
MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013 Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine market share (OBP) Internatio nalSales R2,5 billion 5% 13% +/- R45million =25% of sales (could be much more if OBP is GMP cerified)

Upload: gwenda-dalton

Post on 24-Dec-2015

221 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

MARKET SIZE 2012

| Onderstepoort Biological Products © |22nd February 2013 Page 21

Estimated market size

Estimated total market share ( OBP)

Estimated vaccine market share (OBP)

InternationalSales

R2,5 billion 5% 13% +/-R45million=25% of sales(could be much more if OBP is GMP cerified)

Page 2: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

| Onderstepoort Biological Products © |22nd February 2013 Page 22

Page 3: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

Competitor analysis

| Onderstepoort Biological Products © |22nd February 2013 Page 23

Company Product range

MSD ANIMAL HEALTH (Design Biologics) Complete

PFIZER LABORATORIES Complete

VIRBAC ANIMAL HEALTH 80%

BAYER ANIMAL HEALTH 80%

AFRIVET/ECO AH/COOPER VET PROD 40%

MERIAL 90%

CEVA ANIMAL HEALTH 60%

NOVARTIS 70%

ELANCO ANIMAL HEALTH 40%

OBP (PTY) LTD 20%

BOEHRINGER-INGELHEIM 30%

VTECH VETERINARY SOLUTIONS 20%

BIOTECH VETERINARY 10%

HIPRA 10%

IMMUNO-VET SERVICES CC 10%

STRIDE DISTRIBUTORS 10%

Deltaimmune 10%

Page 4: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

OBP Product Portfolio

Rift Valley Fever – live, inactivated, Clone 13 African horse sickness Bluetongue B-Phemeral Chlamysure Lumpyskin

PI and IBR (in Leukopast 3)• Fowl Pox• ORF• Equine Influenza

| Onderstepoort Biological Products © |22nd February 2013 Page 24

• Actinomyces (Corynebacterium) pyogenes

• Anthrax• Black Quarter• Botulism• Botulism/black quarter • Blue Udder• Brucella Rev 1• Brucella S19• Calf paratyphoid (live & inactivated)• Corynebacterium Ovis• E Coli• Enterotoxaemia (pulpy kidney)• Fowl Typhoid• Gangrene Complex• Haemophilus Coryza• Lamb Dysentry• Leukopast 3 (with IBR and PI)• Leukopast• Pasteurella Bovine• Pasteurella Ovine• Septicum• Swelled Head• Tetanus• Vibrio (Campylobacter)

Other ProductsFrozen infective blood against (in conjunction with OVI)

• Anaplasmosis• Heartwater• Redwater African / Babesiosis • Redwater Asiatic / Babesiosis

Antiserum Diagnostic Reagents (eg dourine, rose bengal)

Bacterial Vaccine Products Viral Vaccine Products

Page 5: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

Company ranking

| Onderstepoort Biological Products © |22nd February 2013 Page 25

COMPANY   YTD POSMSD ANIMAL HEALTH 1

PFIZER LABORATORIES 2

VIRBAC ANIMAL HEALTH 3

BAYER ANIMAL HEALTH 4

AFRIVET/ECO AH/COOPER VET PROD 6

MERIAL 5

CEVA ANIMAL HEALTH 7

NOVARTIS 8

ELANCO ANIMAL HEALTH 9

OBP (PTY) LTD 11

BOEHRINGER-INGELHEIM 10VTECH VETERINARY SOLUTIONS 13

BIOTECH VETERINARY 15

HIPRA 12

IMMUNO-VET SERVICES CC 14

STRIDE DISTRIBUTORS 16

Page 6: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

Market segments: end user market

| Onderstepoort Biological Products © |22nd February 2013 Page 26

Beef CattleDairy cattle

(700)sheep Feedlot

•Combination products• Cost effective• Input is a problem• No Brand loyalty• Can wait on back order

•Combination products• Cost effective• Input is a problem• Brand loyalty• Will not wait on back order

•Combination products• Cost effective• Input very serious problem• Can wait on back order

•Combination products• Cost effective• Input very serious problem• Brand loyalty• Will never wait

35 000 (farmers)1,5 mil/yr

Page 7: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

| Onderstepoort Biological Products © |22nd February 2013 Page 27

Coops Vets WholesalersGov-

?

Distribution segment

Farmer

40% 20%

30%

3-5%

Page 8: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

Product mix per segment

| Onderstepoort Biological Products © |22nd February 2013 Page 28

Beef CattleDairy cattle

(700)Sheep/Goats Feedlot

• Anth/BQ/BOT•Cl. Noyv•LSD, RVF•S19•Gasgangrene,• calf paratyphoid•Pasteurella

•Anth/BQ/BOT•Cl. Noyv•LSD, RVF•S19•Gasgangrene,• calf paratyphoid•Pasteurella•Leucopast & L3•B phemeral

•Anth/BOT•Cl. Noyv• RVF•BT•Past•PK

•Anth/BQ/BOT•Cl. Noyv•LSD, RVF•Gasgangrene,• Calf paratyphoid•Pasteurella•Leucopast & L3

Page 9: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

OBP -Product life cycle

| Onderstepoort Biological Products © |22nd February 2013 Page 29

Mature phase

Declining phase

Growth Phase

80% of bacterial products

LSD, AHS,

Bl vaccines

BT, B. PHEMERAL, RVF

Chlamysure; Turbeculine;

Past bov/ovine

Time

Growth

Page 10: MARKET SIZE 2012 | Onderstepoort Biological Products © |22nd February 2013Page 21 Estimated market size Estimated total market share ( OBP) Estimated vaccine

Sales performance forecast in 3-4 yrs

| Onderstepoort Biological Products © |22nd February 2013 Page 30